400744-57-2

Usage

Uses

Used in Pharmaceutical Research:
5-(3-METHYLPHENYL)-2-FUROIC ACID is used as a precursor in the synthesis of bioactive molecules for pharmaceutical applications. Its unique structure allows for the development of new drugs with potential therapeutic effects.
Used in Organic Synthesis:
In the field of organic synthesis, 5-(3-METHYLPHENYL)-2-FUROIC ACID is utilized as a key intermediate for the production of various organic compounds. Its versatile chemical properties enable the creation of a wide range of molecules with different functionalities.
Used in Specialty Chemicals Production:
5-(3-METHYLPHENYL)-2-FUROIC ACID is used as a building block in the production of specialty chemicals. Its presence in the synthesis process contributes to the development of high-value chemical products with specific applications in various industries.
Used in Organic Intermediates Production:
5-(3-METHYLPHENYL)-2-FUROIC ACID is also employed in the production of organic intermediates, which are essential for the synthesis of more complex organic compounds. Its role in this process highlights its importance in the broader field of chemical manufacturing.

InChI:InChI=1/C12H10O3/c1-8-3-2-4-9(7-8)10-5-6-11(15-10)12(13)14/h2-7H,1H3,(H,13,14)

Upstream product

• 585-70-6 5-bromo-furan-2-carboxylic acid 
• 876189-20-7 (5-(methoxycarbonyl)furan-2-yl)boronic acid 
• 2527-99-3 methyl 5-bromo-2-furoate 
• 17933-03-8 m-tolylboronic acid 
• 852145-99-4 5-(3-methylphenyl)furan-2-carboxylic acid methyl ester 

Relevant academic research and scientific papers

Shedding X-ray Light on the Role of Magnesium in the Activity of Mycobacterium tuberculosis Salicylate Synthase (MbtI) for Drug Design

The Mg2+-dependent Mycobacterium tuberculosis salicylate synthase (MbtI) is a key enzyme involved in the biosynthesis of siderophores. Because iron is essential for the survival and pathogenicity of the microorganism, this protein constitutes an attractiv

Design, synthesis, and electrophysiological evaluation of NS6740 derivatives: Exploration of the structure-activity relationship for alpha7 nicotinic acetylcholine receptor silent activation

The α7 nicotinic acetylcholine receptor (nAChR) silent agonists, able to induce receptor desensitization and promote the α7 metabotropic function, are emerging as new promising therapeutic anti-inflammatory agents. Herein, we report the structure–activity

PHENYLALANINE DERIVATIVES AND THEIR USE AS NON-PEPTIDE GLP-1 RECEPTOR MODULATORS

Provided herein are non-peptide GLP-1 receptor modulator compounds, for example, of Formula I, pharmaceutical compositions comprising such compounds, and processes of preparation thereof. Also provided are methods of their use for the treatment of a metab

Discovery of new C3aR ligands. Part 1: Arginine derivatives

The synthesis and in vitro binding of several new arginine-containing C3aR ligands are reported. DMPK properties and functional activities of selected compounds have been evaluated. One compound is shown to be active in an in vivo model of airway inflamma